Literature DB >> 2790196

Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells.

H Tanaka1, O Tanabe, K Iwato, H Asaoku, H Ishikawa, M Nobuyoshi, M Kawano, A Kuramoto.   

Abstract

The effects of interferon-alpha (IFN alpha) on in vitro proliferation and M-protein secretion in human myeloma cells were investigated. Human myeloma cells were purified from bone marrow aspirates in 12 multiple myeloma patients. Purified myeloma cells were cultured for 48 hours with IFN alpha at its lower concentrations (0.1 to 100 U/mL). The cells were then pulsed with 3H-TdR for the last 12 hours and 3H-TdR uptake was measured (in vitro proliferation). After 48-hour culture, supernatants were harvested and the amount of M-protein in these fluids were measured by enzyme-linked immunosorbent assay (ELISA) (in vitro M-protein secretion). In vitro M-protein secretions of myeloma cells were significantly suppressed even at 0.1 U/mL of IFN alpha, while 3H-TdR uptakes were not so suppressed until 10 or 100 U/mL of IFN alpha were added. The expressions of secretory immunoglobulin (Ig) mRNA of these myeloma cells were also selectively suppressed by IFN alpha. Furthermore, after IFN alpha had been administered intramuscularly, 3 to 6 x 10(6) U/d for at least 1 month, in vitro M-protein secretions of these myeloma cells were decreased compared with those before IFN alpha administration. Therefore, these results suggest that IFN alpha has more sensitive inhibitory effect on M-protein secretion of human myeloma cells rather than on myeloma cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2790196

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Low-dose interferon-alpha in stage-I multiple myeloma and in IgM monoclonal gammopathy. Eastern Cooperative Study Group on Monoclonal Gammopathies.

Authors: 
Journal:  Ann Hematol       Date:  1992-03       Impact factor: 3.673

Review 2.  Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?

Authors:  J Bladé; J Esteve
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

Review 3.  Interferon and multiple myeloma.

Authors:  V M Lauta
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.